NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Tulstrup, MortenGrosjean, Marie
Nielsen, Stine Nygaard
Grell, Kathrine
Wolthers, Benjamin Ole
Wegener, Peder Skov
Jonsson, Olafur Gisli
Lund, Bendik
Harila-Saari, Arja
Abrahamsson, Jonas
Vaitkeviciene, Goda
Pruunsild, Kaie
Toft, Nina
Holm, Mette
Hulegårdh, Erik
Liestøl, Sigurd
Griskevicius, Laimonas
Punab, Mari
Wang, Jinhua
Carroll, William L
Zhang, Zeyu
Dalgaard, Marlene D
Gupta, Ramneek
Nersting, Jacob
Schmiegelow, Kjeld
Issue Date
2018-12-01
Metadata
Show full item recordCitation
NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia. 2018, 32(12):2527-2535 LeukemiaAbstract
The antileukaemic drug 6-mercaptopurine is converted into thioguanine nucleotides (TGN) and incorporated into DNA (DNA-TG), the active end metabolite. In a series of genome-wide association studies, we analysed time-weighted means (Description
To access publisher's full text version of this article click on the hyperlink belowAdditional Links
https://search.proquest.com/docview/2151748244/F7927333457E477APQ/2?accountid=135775https://www.nature.com/articles/s41375-018-0245-3
ae974a485f413a2113503eed53cd6c53
10.1038/s41375-018-0245-3
Scopus Count
Collections
Related articles
- DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
- Authors: Nielsen SN, Grell K, Nersting J, Abrahamsson J, Lund B, Kanerva J, Jónsson ÓG, Vaitkeviciene G, Pruunsild K, Hjalgrim LL, Schmiegelow K
- Issue date: 2017 Apr
- Role of TPMT and ITPA variants in mercaptopurine disposition.
- Authors: Gerbek T, Ebbesen M, Nersting J, Frandsen TL, Appell ML, Schmiegelow K
- Issue date: 2018 Mar
- Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.
- Authors: Tzoneva G, Dieck CL, Oshima K, Ambesi-Impiombato A, Sánchez-Martín M, Madubata CJ, Khiabanian H, Yu J, Waanders E, Iacobucci I, Sulis ML, Kato M, Koh K, Paganin M, Basso G, Gastier-Foster JM, Loh ML, Kirschner-Schwabe R, Mullighan CG, Rabadan R, Ferrando AA
- Issue date: 2018 Jan 25
- Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations.
- Authors: Lancaster DL, Lennard L, Rowland K, Vora AJ, Lilleyman JS
- Issue date: 1998 Jul
- Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia.
- Authors: Dieck CL, Tzoneva G, Forouhar F, Carpenter Z, Ambesi-Impiombato A, Sánchez-Martín M, Kirschner-Schwabe R, Lew S, Seetharaman J, Tong L, Ferrando AA
- Issue date: 2018 Jul 9